China's 315 Gala Exposes Unapproved Exosome Products; Haolin (Tianjin) Biological Technology Co., Ltd. Named

A recent broadcast of China's annual "3·15" Gala in 2026 highlighted issues concerning exosomes, which are being marketed as a "miracle cure." Haolin (Tianjin) Biological Technology Co., Ltd. was specifically named in the report. According to the broadcast, expensive exosome products promoted online are actually bioactive substances secreted during stem cell cultivation. However, within the medical and academic communities, the mechanism of action and clinical testing of these substances remain unclear, with research still largely confined to theoretical and academic stages. Despite the lack of conclusive evidence, some businesses have seized the opportunity to market exosomes, particularly in beauty and anti-aging treatments offered by aesthetic medicine institutions. In contrast to the miraculous claims made in promotional videos, numerous consumer complaints have surfaced online. One user reported, "I tried exosome treatment and ended up with a full-face infection and severe acne." Based on consumer tips, investigators identified a popular exosome product named "Qing Cheng," sold widely in aesthetic clinics. The product was labeled as a "Class II medical device." However, it was revealed that China has not approved any medical devices containing exosomes for market sale. Staff from the manufacturer, Haolin (Tianjin) Biological Technology Co., Ltd., openly admitted that the primary ingredient of their product is exosomes. To evade regulatory oversight, the company used a collagen product license for approval. Public records indicate that Haolin (Tianjin) Biological Technology Co., Ltd. was established in June 2019, with a legal representative named Zhang Chen and registered capital of 10 million yuan. Its business scope includes development and application of human stem cell technology, gene diagnosis and therapy technology, as well as cell technology R&D. The company is jointly owned by Wan Zhiheng and Zhang Chen. It has invested in three other enterprises: Haolin Biopharmaceutical (Tianjin) Co., Ltd., Haolin (Beijing) Medical Technology Co., Ltd., and Tianjin Queming Biomedical Engineering Research Co., Ltd. Attempts to contact Haolin (Tianjin) Biological Technology Co., Ltd. via its registered business phone number were unsuccessful as of the time of reporting.